Literature DB >> 23333438

miRNA expression in pediatric failing human heart.

Brian L Stauffer1, Gloria Russell, Karin Nunley, Shelley D Miyamoto, Carmen C Sucharov.   

Abstract

miRNAs are short regulatory RNAs that can regulate gene expression through interacting with the 3'UTR of target mRNAs. Although the role of miRNAs has been extensively studied in adult human and animal models of heart disease, nothing is known about their expression in pediatric heart failure patients. Different than adults with heart failure, pediatric patients respond well to phosphodiesterase inhibitor (PDEi) treatment, which is safe in the outpatient setting, results in fewer heart failure emergency department visits, fewer cardiac hospital admissions and improved NYHA classification. We have recently shown that pediatric heart failure patients display a unique molecular profile that is different from adults with heart failure. In this study we show for the first time that pediatric heart failure patients display a unique miRNA profile, and that expression of some miRNAs correlate with response to PDEi treatment. Moreover, we show that expression of Smad4, a potential target for PDEi-regulated miRNAs, is normalized in PDEi-treated patients. Since miRNAs may be used as therapy for human heart failure, our results underscore the importance of defining the molecular characteristics of pediatric heart failure patients, so age-appropriate therapy can be designed for this population.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23333438      PMCID: PMC3694420          DOI: 10.1016/j.yjmcc.2013.01.005

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  14 in total

1.  The impact of changing medical therapy on transplantation-free survival in pediatric dilated cardiomyopathy.

Authors:  Paul F Kantor; Jonathan R Abraham; Anne I Dipchand; Lee N Benson; Andrew N Redington
Journal:  J Am Coll Cardiol       Date:  2010-03-30       Impact factor: 24.094

2.  Chronic inotropic therapy in end-stage heart failure.

Authors:  Paul J Hauptman; Peter Mikolajczak; Anil George; Clinton J Mohr; Robert Hoover; Jason Swindle; Mark A Schnitzler
Journal:  Am Heart J       Date:  2006-12       Impact factor: 4.749

Review 3.  Role of microRNAs in cardiac remodeling and heart failure.

Authors:  Veli K Topkara; Douglas L Mann
Journal:  Cardiovasc Drugs Ther       Date:  2011-04       Impact factor: 3.727

4.  Incidence, causes, and outcomes of dilated cardiomyopathy in children.

Authors:  Jeffrey A Towbin; April M Lowe; Steven D Colan; Lynn A Sleeper; E John Orav; Sarah Clunie; Jane Messere; Gerald F Cox; Paul R Lurie; Daphne Hsu; Charles Canter; James D Wilkinson; Steven E Lipshultz
Journal:  JAMA       Date:  2006-10-18       Impact factor: 56.272

5.  miRNA expression in the failing human heart: functional correlates.

Authors:  Carmen Sucharov; Michael R Bristow; J David Port
Journal:  J Mol Cell Cardiol       Date:  2008-05-15       Impact factor: 5.000

6.  Requirement for Ca2+/calmodulin-dependent kinase II in the transition from pressure overload-induced cardiac hypertrophy to heart failure in mice.

Authors:  Haiyun Ling; Tong Zhang; Laetitia Pereira; Christopher Kable Means; Hongqiang Cheng; Yusu Gu; Nancy D Dalton; Kirk L Peterson; Ju Chen; Donald Bers; Joan Heller Brown; Joan Heller Brown
Journal:  J Clin Invest       Date:  2009-04-20       Impact factor: 14.808

7.  Outpatient continuous parenteral inotropic therapy as bridge to transplantation in children with advanced heart failure.

Authors:  Jack F Price; Jeffrey A Towbin; William J Dreyer; Brady S Moffett; Naomi J Kertesz; Sarah K Clunie; Susan W Denfield
Journal:  J Card Fail       Date:  2006-03       Impact factor: 5.712

Review 8.  Capturing adenylyl cyclases as potential drug targets.

Authors:  Sandra Pierre; Thomas Eschenhagen; Gerd Geisslinger; Klaus Scholich
Journal:  Nat Rev Drug Discov       Date:  2009-04       Impact factor: 84.694

9.  SMAD-proteins as a molecular switch from hypertrophy to apoptosis induction in adult ventricular cardiomyocytes.

Authors:  Jacqueline Heger; Saskia C Peters; Hans-Michael Piper; Gerhild Euler
Journal:  J Cell Physiol       Date:  2009-08       Impact factor: 6.384

10.  Carvedilol for children and adolescents with heart failure: a randomized controlled trial.

Authors:  Robert E Shaddy; Mark M Boucek; Daphne T Hsu; Robert J Boucek; Charles E Canter; Lynn Mahony; Robert D Ross; Elfriede Pahl; Elizabeth D Blume; Debra A Dodd; David N Rosenthal; Jeri Burr; Bernie LaSalle; Richard Holubkov; Mary Ann Lukas; Lloyd Y Tani
Journal:  JAMA       Date:  2007-09-12       Impact factor: 56.272

View more
  25 in total

1.  Transgenic over-expression of YY1 induces pathologic cardiac hypertrophy in a sex-specific manner.

Authors:  Brian L Stauffer; Karen Dockstader; Gloria Russell; Jamie Hijmans; Lisa Walker; Mackenzie Cecil; Kimberly Demos-Davies; Allen Medway; Timothy A McKinsey; Carmen C Sucharov
Journal:  Biochem Biophys Res Commun       Date:  2015-04-29       Impact factor: 3.575

Review 2.  Genetics of paediatric cardiomyopathies.

Authors:  Stephanie M Ware
Journal:  Curr Opin Pediatr       Date:  2017-10       Impact factor: 2.856

3.  MicroRNA values in children with rheumatic carditis: a preliminary study.

Authors:  Gokhan Gumus; Dilek Giray; Onur Bobusoglu; Lulufer Tamer; Derya Karpuz; Olgu Hallioglu
Journal:  Rheumatol Int       Date:  2018-05-29       Impact factor: 2.631

4.  New mechanistic and therapeutic targets for pediatric heart failure: report from a National Heart, Lung, and Blood Institute working group.

Authors:  Kristin M Burns; Barry J Byrne; Bruce D Gelb; Bernhard Kühn; Leslie A Leinwand; Seema Mital; Gail D Pearson; Mark Rodefeld; Joseph W Rossano; Brian L Stauffer; Michael D Taylor; Jeffrey A Towbin; Andrew N Redington
Journal:  Circulation       Date:  2014-07-01       Impact factor: 29.690

5.  Exosomes from pediatric dilated cardiomyopathy patients modulate a pathological response in cardiomyocytes.

Authors:  Xuan Jiang; Juliana Sucharov; Brian L Stauffer; Shelley D Miyamoto; Carmen C Sucharov
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-01-27       Impact factor: 4.733

6.  Alteration of cardiolipin biosynthesis and remodeling in single right ventricle congenital heart disease.

Authors:  Anastacia M Garcia; Jessica C McPhaul; Genevieve C Sparagna; Danielle A Jeffrey; Raleigh Jonscher; Sonali S Patel; Carmen C Sucharov; Brian L Stauffer; Shelley D Miyamoto; Kathryn C Chatfield
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-02-14       Impact factor: 4.733

7.  Molecular Changes in Children with Heart Failure Undergoing Left Ventricular Assist Device Therapy.

Authors:  Elizabeth Medina; Carmen C Sucharov; Penny Nelson; Shelley D Miyamoto; Brian L Stauffer
Journal:  J Pediatr       Date:  2016-11-29       Impact factor: 4.406

8.  Micro-RNA expression in hypoplastic left heart syndrome.

Authors:  Carmen C Sucharov; Juliana Sucharov; Anis Karimpour-Fard; Karin Nunley; Brian L Stauffer; Shelley D Miyamoto
Journal:  J Card Fail       Date:  2014-10-05       Impact factor: 5.712

Review 9.  Advances in heart failure therapy in pediatric patients with dilated cardiomyopathy.

Authors:  Stefan Rupp; Christian Jux
Journal:  Heart Fail Rev       Date:  2018-07       Impact factor: 4.214

10.  Pediatric dilated cardiomyopathy hearts display a unique gene expression profile.

Authors:  Philip D Tatman; Kathleen C Woulfe; Anis Karimpour-Fard; Danielle A Jeffrey; James Jaggers; Joseph C Cleveland; Karin Nunley; Matthew Rg Taylor; Shelley D Miyamoto; Brian L Stauffer; Carmen C Sucharov
Journal:  JCI Insight       Date:  2017-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.